Fol. Biol. 2013, 59, 162-167
https://doi.org/10.14712/fb2013059040162
Inhibition of mTORC1 by SU6656, the Selective Src Kinase Inhibitor, Is Not Accompanied by Activation of Akt/PKB Signalling in Melanoma Cells
References
1. , A., Paul, E., Schartl, M. (1987) Expression of the c-src protooncogene in human skin tumors. Cancer Res. 47, 235-240.
2. , R. A., Broome, M. A., Liu, X., Wu, J., Gishizky, M., Sun, L., Courtneidge, S. A. (2000) SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol. Cell Biol. 20, 9018-9027.
<https://doi.org/10.1128/MCB.20.23.9018-9027.2000>
3. , D., Chen, C. H., Shaikenov, T., Agarwal, N. K., Peterson, T. R., Addona, T. A., Keshishian, H., Carr, S. A., Magnuson, M. A., Sabatini, D. M., Sarbassov, d. D. (2010) Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Mol. Cancer Res. 8, 896-906.
<https://doi.org/10.1158/1541-7786.MCR-09-0409>
4. , B., Tardell, C., Higgins, B., Packman, K., Boylan, J. F., Niu, H. (2012) BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One 7, e42598.
<https://doi.org/10.1371/journal.pone.0042598>
5. , C. C., Asara, J. M., Manning, B. D. (2009) Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol. Cell Biol. 29, 5657-5670.
<https://doi.org/10.1128/MCB.00735-09>
6. , A. J., Crown, J., Clynes, M., O’Donovan, N. (2008) Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J. Transl. Med. 6, 53-56.
<https://doi.org/10.1186/1479-5876-6-53>
7. , J., Arozarena, I., Ehrhardt, M., Wellbrock, C. (2013) Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene 32, 86-96.
<https://doi.org/10.1038/onc.2012.25>
8. , C., Journe, F., Ghanem, G., Jimenez-Cervantes, C., Garcia-Borron, J. C. (2012) Functional status and relationships of melanocortin 1 receptor signaling to the cAMP and extracellular signal-regulated protein kinases 1 and 2 pathways in human melanoma cells. Int. J. Biochem. Cell Biol. 44, 2244-2252.
<https://doi.org/10.1016/j.biocel.2012.09.008>
9. , J., Cubitt, C., Daud, A. (2007) The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin. Ther. Targets 11, 91-100.
<https://doi.org/10.1517/14728222.11.1.91>
10. , J., Cubitt, C. L., Zhang, S., Munster, P. N., Yu, H., Sullivan, D. M., Jove, R., Messina, J. L., Daud, A. I. (2009) Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 19, 167-175.
<https://doi.org/10.1097/CMR.0b013e328304974c>
11. , R. C., Mueckler, M. (2005) mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280, 40406-40416.
<https://doi.org/10.1074/jbc.M508361200>
12. , T., Qiu, y. (2003) Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation. J. Biol. Chem. 278, 15789-15793.
<https://doi.org/10.1074/jbc.M212525200>
13. , L. A., Carriere, A., Moreau, J., Roux, P. P. (2010) mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol. Cell Biol. 30, 908-921.
<https://doi.org/10.1128/MCB.00601-09>
14. , D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., Sabatini, D. M. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175.
<https://doi.org/10.1016/S0092-8674(02)00808-5>
15. , R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., Hall, M. N. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457-468.
<https://doi.org/10.1016/S1097-2765(02)00636-6>
16. , X. M., Blenis, J. (2009) Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307-318.
<https://doi.org/10.1038/nrm2672>
17. , R., Feldberg, L. R., Lucas, J., Chaudhary, I., Dehnhardt, C., Santos, E. D., Chen, Z., dos Santos, O., AyralKaloustian, S., Venkatesan, A., Hollander, I. (2011) Antitumor efficacy of PKI-587, a highly potent dual PI3K/ mTOR kinase inhibitor. Clin. Cancer Res. 17, 3193-3203.
<https://doi.org/10.1158/1078-0432.CCR-10-1694>
18. , D. D., Guertin, D. A., Ali, S. M., Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
<https://doi.org/10.1126/science.1106148>
19. , C., Warne, P. H., Magnuson, M. A., Pende, M., Downward, J. (2010) Rictor is a novel target of p70 S6 kinase-1. Oncogene 29, 1003-1016.
<https://doi.org/10.1038/onc.2009.401>
20. , J., Novotná, H., Ghanem, G. (2001) Transcriptional repression of the microphthalmia gene in melanoma cells correlates with the unresponsiveness of target genes to ectopic microphthalmia-associated transcription factor. J. Invest Dermatol. 117, 1505-1511.
<https://doi.org/10.1046/j.0022-202x.2001.01563.x>
21. , E., Perez-Garcia, J., Tabernero, J. (2011) Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol. Cancer Ther. 10, 395-403.
<https://doi.org/10.1158/1535-7163.MCT-10-0905>
22. , M., Turečková, J., Kučerová, D., Šloncová, E., Vachtenheim, J., Tuháčková, Z. (2008) Regulation of mTORC1 signaling by Src kinase activity is Akt1independent in RSV-transformed cells. Neoplasia 10, 99-107.
<https://doi.org/10.1593/neo.07905>
23. , S., Loewith, R., Hall, M. N. (2006) TOR signaling in growth and metabolism. Cell 124, 471-484.
<https://doi.org/10.1016/j.cell.2006.01.016>
24. , B., Jeong, J. H., Asara, J. M., Yuan, Y. Y., Granter, S. R., Chin, L., Cantley, L. C. (2009) Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 33, 237-247.
<https://doi.org/10.1016/j.molcel.2008.12.026>
